UCB SA (UCBJF)
OTCMKTS
· Delayed Price · Currency is USD
174.00
-1.00 (-0.57%)
At close: Nov 18, 2024
UCB SA Employees
As of December 31, 2023, UCB SA had 9,083 total employees, including 8,450 full-time and 633 part-time employees. The number of employees increased by 380 or 4.37% compared to the previous year.
Employees
9,083
Change (1Y)
380
Growth (1Y)
4.37%
Revenue / Employee
$649,309
Profits / Employee
$28,572
Market Cap
35.50B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Sandoz Group AG | 22,633 |
Telix Pharmaceuticals Limited | 234 |
Elekta AB (publ) | 4,718 |
Ryman Healthcare Limited | 7,700 |
Verano Holdings Corp. | 3,900 |
Vireo Growth Inc. | 490 |
Medexus Pharmaceuticals Inc. | 82 |
UCB SA News
- 4 days ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 4 days ago - FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease - Benzinga
- 4 days ago - UCB gets FDA approval for Bimzelx for hidradenitis suppurativa - Seeking Alpha
- 5 days ago - Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - Seeking Alpha
- 12 days ago - United Community Banks: Too Rich For My Blood - Seeking Alpha
- 5 weeks ago - Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy - Seeking Alpha
- 2 months ago - UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024 - Benzinga
- 2 months ago - UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024 - Benzinga